MAP4K4: an emerging therapeutic target in cancer.
MAP4K4: an emerging therapeutic target in cancer.
复制标题
DOI：
10.1186/s13578-016-0121-7
复制
发表时间：
2016
影响因子：
7.5
通讯作者：
Hu J
中科院分区：
文献类型：
--
作者：
Gao X;Gao C;Liu G;Hu J
丝氨酸/苏氨酸激酶MAP4K4是Ste20p（不育20蛋白）家族的成员。MAP4K4最初是在1995年被发现的，是酿酒酵母交配通路中的一个关键激酶，后来被发现参与了许多方面的细胞功能和许多生物学和病理过程。MAP4K4在免疫、炎症、代谢和心血管疾病中的作用已被认识。关于MAP4K4在癌症中的作用的信息非常有限，但越来越多的证据表明，MAP4K4在癌症中也起着重要作用，MAP4K4可能是一种新的可操作的癌症治疗靶点。本文综述了目前对MAP4K4调控和MAP4K4在癌症中的作用的认识。map4k4特异性抑制剂最近被开发出来。我们希望这篇综述文章能够倡导更多关于MAP4K4在癌症中的基础和临床前研究，最终为MAP4K4抑制剂在癌症患者的临床前和临床试验提供生物学和机制依据。
The serine/threonine kinase MAP4K4 is a member of the Ste20p (sterile 20 protein) family. MAP4K4 was initially discovered in 1995 as a key kinase in the mating pathway in Saccharomyces cerevisiae and was later found to be involved in many aspects of cell functions and many biological and pathological processes. The role of MAP4K4 in immunity, inflammation, metabolic and cardiovascular disease has been recognized. Information regarding MAP4K4 in cancers is extremely limited, but increasing evidence suggests that MAP4K4 also plays an important role in cancer and MAP4K4 may represent a novel actionable cancer therapeutic target. This review summarizes our current understanding of MAP4K4 regulation and MAP4K4 in cancer. MAP4K4-specific inhibitors have been recently developed. We hope that this review article would advocate more basic and preclinical research on MAP4K4 in cancer, which could ultimately provide biological and mechanistic justifications for preclinical and clinical test of MAP4K4 inhibitor in cancer patients.
登录
查看更多内容
五基因特征作为结直肠癌转移和生存的潜在预测因子
影响因子：
7.3
作者：
Hao, Jun-Mei;Chen, Juan-Zhi;Li, Jian-Ming
通讯作者：
Li, Jian-Ming
影响因子：
5.3
作者：
Becker, E;Huynh-Do, U;Skolnik, EY
通讯作者：
Skolnik, EY
影响因子：
4.8
作者：
Fu, CA;Shen, M;Luo, Y
通讯作者：
Luo, Y
影响因子：
3.5
作者：
Dan, I;Watanabe, NM;Kusumi, A
通讯作者：
Kusumi, A
影响因子：
5.3
作者：
Danai, Laura V.;Flach, Rachel J. Roth;Czech, Michael P.
通讯作者：
Czech, Michael P.